By Chris Wack
Allarity Therapeutics and Detsamma Investments, trading as FivepHusion, have entered into a clinical collaboration agreement for Deflexifol.
Under this agreement, Allarity will support FivepHusion's future clinical development of Deflexifol for the treatment of solid tumors by using certain of Allarity's drug-specific DRP companion diagnostics to potentially select patients for enrollment and treatment in clinical trials of Deflexifol as a monotherapy and in combination with other drugs.
Deflexifol is a novel anti-cancer drug reformulation designed to address the safety and efficacy limitations of standard-of-care 5FU chemotherapy.
FivepHusion expects to start a phase 1b/2a study investigating Deflexifol in combination with oxaliplatin and bevacizumab in the first line treatment of unresectable metastatic colorectal cancer patients in the second half of 2023. This 50-patient trial is designed to evaluate the safety, tolerability and pharmacokinetics of Deflexifol. A secondary endpoint is the assessment of objective response and overall survival of patients treated.
Financial terms of the clinical collaboration, option and potential license aren't disclosed. If FivepHusion exercises its option right and receives a license to the Allarity DRP companion diagnostic technology related to Deflexifol, Allarity will receive certain milestone payments triggered by regulatory approvals of Deflexifol and attainment of drug sales benchmarks.
Allarity shares were up 30% to $3.43 in premarket trading.
Write to Chris Wack at chris.wack@wsj.com
